Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Vaccinations01:51

Vaccinations

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD46 regulates hepatitis B virus entry by modulating cell-surface NTCP levels through cis-interaction.

Journal of molecular cell biology·2025
Same author

ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses and neutralizing antibody induction.

Journal of virology·2025
Same author

Poly(I:C) signaling induces robust CXCL10 production and apoptosis in human esophageal squamous cell carcinoma cells.

Human cell·2025
Same author

Th1 adjuvant ARNAX, in combination with radiation therapy, enhances tumor regression in mouse tumor-implant models.

Immunology letters·2024
Same author

Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination.

Cells·2023
Same author

Innate-Acquired Linkage in Immunotherapy.

Cells·2023
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: May 15, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

[Basic background for adjuvant immunotherapy].

Tsukasa Seya1

  • 1Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 25, 2012
PubMed
Summary
This summary is machine-generated.

Pattern recognition receptors (PRRs), like Toll-like receptors (TLRs), sense infections. This review explores TLRs as adjuvants for cancer immunotherapy, enhancing innate and adaptive immunity against tumors.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Context:

  • Pattern recognition receptors (PRRs) are crucial for innate immunity, detecting microbial patterns to initiate host defense.
  • Toll-like receptors (TLRs), a key class of PRRs, are well-known for their role in dendritic cell maturation and immune responses.
  • Cancer differs from infection as it presents antigens but lacks the necessary PRR agonists (adjuvants) to stimulate a robust immune response.

Purpose:

  • To review the function of Toll-like receptors (TLRs) as adjuvant receptors.
  • To explore the potential of TLRs in evoking innate and cognate immunity against cancer.
  • To discuss the advancements in clinical studies utilizing TLRs for antitumor immunotherapy.

Summary:

  • This review examines the role of Toll-like receptors (TLRs) as critical components of the innate immune system that can be leveraged as adjuvants in cancer therapy.
  • TLRs recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), bridging innate and adaptive immunity.
  • The discussion highlights how TLR agonists can overcome the immunologically 'cold' nature of tumors by providing the missing adjuvant signal, thereby enhancing antigen presentation and T-cell mediated antitumor responses.

Impact:

  • Understanding TLRs as adjuvants offers a promising strategy for developing novel cancer immunotherapies.
  • Clinical studies are exploring TLR agonists to improve the efficacy of existing cancer treatments and overcome treatment resistance.
  • Leveraging TLRs could lead to more effective and targeted antitumor immune responses, improving patient outcomes in oncology.